The vaporiser allows cannabis to be taken in the form of vapors extracted from oils or herbs.
This phase of the project is expected to be completed by the end of July, well ahead of schedule and will be followed by commercialisation.
Software makes vaporise unique
What makes the vaporiser unique is its embedment in the medically certified software infrastructure of BodyTel GmbH, a wholly owned subsidiary of Lifespot.
The BodyTel infrastructure allows both patients and authorised physicians to retrieve and evaluate the readings and data collected by the vaporiser.
Large-scale market that is growing
With the all-in-one vaporiser integrated into the BodyTel system, Lifespot Health is addressing a large growth market.
Estimates state that the global market for legal cannabis applications will grow to over US$57 billion in annual revenue by 2027.
Of these, more than US$ 19 billion will be spent on medical cannabis applications.
Collaborating for funding
Collaboration with well-known international cannabis companies to secure further funding until the end of the September 2018 quarter, as well as sales cooperation, are advancing well.
Lifespot expects to remain ahead of schedule in both development and commercial milestones.